Strategic Clinical Research Group | Willow Park, TX
Status and phase
Conditions
Treatments
About
This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treated with faricimab. The study population will consist of participants ≥18 years of age who self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander; in addition, a cohort of Asian Indian participants will be enrolled in India.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Main Phase General Inclusion Criteria:
Main Phase Ocular Inclusion Criteria for Study Eye:
Long-Term Extension (LTE) Inclusion Criteria:
Exclusion criteria
Main Phase General Exclusion Criteria:
Main Phase Ocular Exclusion Criteria for Study Eye:
Main Phase Ocular Exclusion Criteria for Non-Study Eye:
Long-Term Extension (LTE) Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
218 participants in 2 patient groups
Loading...
Central trial contact
Reference Study ID Number: ML43435 https://forpatients.roche.com/
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal